Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis

Journal of International Medical Research

Volumn 37, Issue 3, 2009, Pages 892-898

  Kitamura, Noboru ^a   Matsukawa, Y ^a   Takei, M ^a   Sawada, S ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker (ARB); Angiotensin converting enzyme inhibitor (ACEI); Losartan; Lupus nephritis; Proteinuria; Renal function; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DOUBLE STRANDED DNA ANTIBODY; ENALAPRIL; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; COMPLEMENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HUMAN; HYPOTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; OBSERVATIONAL STUDY; PROTEINURIA; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; ADOLESCENT; ANIMAL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, ANTINUCLEAR; BLOOD PRESSURE; COMPLEMENT SYSTEM PROTEINS; CREATININE; FEMALE; HUMANS; LOSARTAN; LUPUS NEPHRITIS; MIDDLE AGED; PROTEINURIA;

EID: 70349232428     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700335     Document Type: Article

References (23)

1. Siamopoulos KC, Kalaitzidis RG: Inhibition of the renin-angiotensin system and chronic kidney disease. Int Urol Nephrol 2008; 40: 1015-1025.
2. Mangrum AJ, Bakris GL: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004; 24: 168-175. (Pubitemid 38387858)
3. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860. (Pubitemid 34940824)
4. Abe H, Minatoguchi S, Ohashi H, et al: Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy. Hypertens Res 2007; 30: 929-935. (Pubitemid 350120970)
5. Smith DM, Fortune-Faulkner EM, Spurbeck BL: Lupus nephritis: pathophysiology, diagnosis, and collaborative management. Nephrol Nurs J 2000; 27: 199-204, 209-211.
6. Foote A, Erfurt JC: Hypertension control at the work site. Comparison of screening and referral alone, referral and follow-up, and on-site treatment. N Engl J Med 1983; 308: 809-813.
7. Seshan SV, Jennette JC: Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med 2009; 33: 233-248.
8. Carette S, Klippel JH, Decker JL, et al: Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983; 99: 1-8.
9. Austin HA, Muenz LR, Joyce KM, et al: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
10. Austin HA, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619. (Pubitemid 16132725)
11. Fiehn C, Hajjar Y, Mueller K, et al: Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435-439. (Pubitemid 36469735)
12. Austin HA, Balow JE: Natural history and treatment of lupus nephritis. Semin Nephrol 1999; 19: 2-11. (Pubitemid 29048841)
13. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
14. Wapstra FH, Navis G, de Jong PE, et al: Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol 1996; 4: 47-52. (Pubitemid 26421856)
15. Cooper M, Boner G: Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabet Med 2004; 21(suppl 1): 15-18. (Pubitemid 38315247)
16. Dillon JJ: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol 2004; 24: 218-224. (Pubitemid 38685991)
17. Yang Y, Ohta K, Shimizu M, et al: Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 2005; 64: 35-40. (Pubitemid 40975063)
18. Kanda H, Kubo K, Tateishi S, et al: Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14: 288-292. (Pubitemid 40559174)
19. Lafayette RA, Mayer G, Park SK, et al: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
20. Kanno Y, Okada H, Suzuki H, et al: Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats. Blood Press Suppl 1994; 5: 67-70. (Pubitemid 24380442)
21. De Albuquerque DA, Saxena V, Adams DE, et al: An ACE inhibitor reduces Th2 cytokines and TGF-β1 and TGF-β2 isoforms in murine lupus nephritis. Kidney Int 2004; 65: 846-859. (Pubitemid 38251060)
22. Esteban V, Ruperez M, Vita JR, et al: Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl 2003; 86: S33-S38. (Pubitemid 37159625)
23. Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21-30. (Pubitemid 38208418)